Baxter(US:BAX) Globenewswire·2025-12-13 14:25Core Points - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7] - The lawsuit covers individuals who purchased Baxter common stock between February 23, 2022, and October 29, 2025, with a deadline of December 15, 2025, for investors to apply as lead plaintiffs [7] Allegation Details - The complaint claims that Baxter failed to disclose critical information about the Novum LVP, including systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3] - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm [3] - The lawsuit suggests that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for further information [4] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across state and federal courts [5]